US 12,290,558 B2
SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens
Patrick Soon-Shiong, Culver City, CA (US); Peter Sieling, Culver City, CA (US); Kayvan Niazi, Culver City, CA (US); Shahrooz Rabizadeh, Agoura Hills, CA (US); Lise Geissert, Culver City, CA (US); Annie Shin, Culver City, CA (US); Adrian Rice, Culver City, CA (US); Elizabeth Gabitzsch, Culver City, CA (US); Jeffrey Safrit, Culver City, CA (US); and Leonard Sender, Culver City, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Oct. 17, 2023, as Appl. No. 18/488,629.
Application 18/488,629 is a continuation of application No. 17/198,164, filed on Mar. 10, 2021, granted, now 11,857,620.
Application 17/198,164 is a continuation in part of application No. 17/082,994, filed on Oct. 28, 2020, abandoned.
Application 17/198,164 is a continuation in part of application No. 16/883,263, filed on May 26, 2020, granted, now 11,684,668, issued on Jun. 27, 2023.
Application 17/198,164 is a continuation in part of application No. 16/880,804, filed on May 21, 2020, abandoned.
Claims priority of provisional application 63/135,380, filed on Jan. 8, 2021.
Claims priority of provisional application 63/121,102, filed on Dec. 3, 2020.
Claims priority of provisional application 63/118,697, filed on Nov. 26, 2020.
Claims priority of provisional application 63/117,922, filed on Nov. 24, 2020.
Claims priority of provisional application 63/117,460, filed on Nov. 24, 2020.
Claims priority of provisional application 63/117,847, filed on Nov. 24, 2020.
Claims priority of provisional application 63/115,127, filed on Nov. 18, 2020.
Claims priority of provisional application 63/082,145, filed on Sep. 23, 2020.
Claims priority of provisional application 63/080,887, filed on Sep. 21, 2020.
Claims priority of provisional application 63/069,598, filed on Aug. 24, 2020.
Claims priority of provisional application 63/067,033, filed on Aug. 18, 2020.
Claims priority of provisional application 63/064,157, filed on Aug. 11, 2020.
Claims priority of provisional application 63/059,975, filed on Aug. 1, 2020.
Claims priority of provisional application 63/053,691, filed on Jul. 19, 2020.
Claims priority of provisional application 63/036,445, filed on Jun. 9, 2020.
Claims priority of provisional application 63/022,146, filed on May 8, 2020.
Claims priority of provisional application 63/016,048, filed on Apr. 27, 2020.
Claims priority of provisional application 63/016,241, filed on Apr. 27, 2020.
Claims priority of provisional application 63/009,960, filed on Apr. 14, 2020.
Claims priority of provisional application 63/010,010, filed on Apr. 14, 2020.
Claims priority of provisional application 62/991,504, filed on Mar. 18, 2020.
Claims priority of provisional application 62/988,328, filed on Mar. 11, 2020.
Prior Publication US 2024/0075129 A1, Mar. 7, 2024
Int. Cl. A61K 39/215 (2006.01); C12N 15/861 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); C12N 15/86 (2006.01)
CPC A61K 39/215 (2013.01) [C12N 15/861 (2013.01); A61K 39/39 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61P 31/14 (2018.01); C07K 2319/06 (2013.01); C12N 15/86 (2013.01); C12N 2710/10343 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A boost vaccine composition for use in inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in mucosal tissue of a patient,
wherein the patient has been primed with a SARS-CoV2 vaccine, and
wherein the boost vaccine composition comprises a replication defective human adenovirus serotype 5 (hAd5), and wherein the hAd5 comprises an E1 gene region deletion, an E2b gene region deletion, a nucleic acid portion that encodes a SARS-CoV2 S protein, and a nucleic acid portion that encodes a chimeric protein comprising a SARS-CoV2 nucleocapsid (N) protein and an endosomal targeting sequence.